, Volume 4, Issue 1, pp 123–125 | Cite as


  • Catherine ChironEmail author


Stiripentol (STP) is a new antiepileptic compound made by Biocodex. It recently proved to increase the GABAergic transmissionin vitro in an experimental model of immature rat. Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19in vivo in epileptic patients. Whereas the studies in adult patients were disappointing, the trials conducted in pediatric populations demonstrated a specific efficacy of STP in severe myoclonic epilepsy in infancy, Dravet syndrome, when combined with valproate and clobazam. Based on these results, STP was granted orphan drug status in the European Union for the treatment of Dravet syndrome. The French experience in compassionate use suggests that STP might also be of benefit when combined with carbamazepine in pediatric patients with pharmacoresistant partial epilepsy. The interactions of STP with a large number of drugs need to be carefully taken into account, with doses of the combined antiepileptic drugs adjusted to improve the tolerability of the therapeutic association.

Key Words

Stiripentol antiepileptic drugs childhood epilepsy severe myoclonic epilepsy cytochrome P450 interactions 


  1. 1.
    Poisson M, Huguet F, Savattier A, Bakri-Logeais F, Narcisse G. A new type of anticonvulsant, stiripentol: pharmacological profile and neurochemical study. Arzneimittelforschung 1984;34: 199–204.PubMedGoogle Scholar
  2. 2.
    Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia 2006;47: 704–716.PubMedCrossRefGoogle Scholar
  3. 3.
    Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997;62: 490–504.PubMedCrossRefGoogle Scholar
  4. 4.
    Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000;356: 1638–1642.PubMedCrossRefGoogle Scholar
  5. 5.
    Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984;36: 661–669.PubMedCrossRefGoogle Scholar
  6. 6.
    Tran A, Vauzelle-Kervroedan F, Rey E, et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol 1996;50: 497–500.PubMedCrossRefGoogle Scholar
  7. 7.
    Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 2006;34: 608–611.PubMedCrossRefGoogle Scholar
  8. 8.
    Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999;40: 1618–1626.PubMedCrossRefGoogle Scholar
  9. 9.
    Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology 2000;54: 2237–2244.PubMedGoogle Scholar
  10. 10.
    Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52: 1882–1887.PubMedGoogle Scholar
  11. 11.
    Chiron C, Tonnelier S, Rey E, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol 2006;21: 496–502.PubMedGoogle Scholar
  12. 12.
    Thanh TN, Chiron C, Dellatolas G, et al. Efficacité et tolérance à long terme du stiripentol dans le traitement de l’épilepsie myoclonique sévère du nourrisson (syndrome de Dravet) [Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet’s syndrome)]. Arch Pediatr 2002;9: 1120–1127.PubMedCrossRefGoogle Scholar
  13. 13.
    Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998;29: 147–154.PubMedCrossRefGoogle Scholar
  14. 14.
    Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000;9: 590–594.PubMedCrossRefGoogle Scholar
  15. 15.
    Ceulemans B, Boel M, Claes L, et al. Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol 2004; 19: 516–521.PubMedCrossRefGoogle Scholar
  16. 16.
    Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 2002;49: 45–48.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2007

Authors and Affiliations

  1. 1.Service de Neurologie et Métabolisme, Hôpital NeckerINSERM U663ParisFrance
  2. 2.University Renè Descartes, Paris VParis
  3. 3.AP-HP, Department of Neurology and MetabolismNecker HospitalParisFrance

Personalised recommendations